Cibus Announces Positive Field Trial Results for Second-Generation Herbicide Tolerance (HT2) Edited Canola
Cibus (NASDAQ:CBUS) has announced successful field trial results for its second-generation herbicide tolerance (HT2) edited Canola trait. The trials, conducted at multiple US locations during the 2025 growing season, validated the trait's performance under real-world conditions following positive greenhouse trials.
The HT2 trait offers enhanced weed management capabilities, allowing for fewer herbicide applications and compatibility with other herbicide resistance traits. This development demonstrates the effectiveness of Cibus' Rapid Trait Development System™ (RTDS®), which significantly reduces trait development time compared to conventional breeding or GMO approaches.
Cibus (NASDAQ:CBUS) ha annunciato i risultati positivi dei test sul campo per la sua seconda generazione della tolleranza agli erbicidi (HT2) nel tratto di canola modificata. I test, condotti in diverse località statunitensi durante la stagione di crescita 2025, hanno convalidato le prestazioni del tratto in condizioni reali, a seguito di esiti positivi dei test in serra.
Il tratto HT2 offre capacità migliorate di gestione delle erbe infestanti, consentendo meno interventi erbicidi e la compatibilità con altri tratti di resistenza agli erbicidi. Questo sviluppo dimostra l'efficacia del Rapid Trait Development System™ (RTDS®) di Cibus, che riduce significativamente i tempi di sviluppo del tratto rispetto ai metodi di allevamento convenzionali o agli approcci GMO.
Cibus (NASDAQ:CBUS) ha anunciado resultados exitosos de ensayos de campo para su rasgo de tolerancia a herbicidas (HT2) de segunda generación en canola editada. Los ensayos, realizados en múltiples lugares de Estados Unidos durante la temporada de cultivo 2025, validaron el rendimiento del rasgo en condiciones reales tras resultados positivos en invernadero.
El rasgo HT2 ofrece capacidades mejoradas de manejo de malezas, permitiendo menos aplicaciones de herbicidas y compatibilidad con otros rasgos de resistencia a herbicidas. Este desarrollo demuestra la eficacia del Rapid Trait Development System™ (RTDS®) de Cibus, que reduce significativamente el tiempo de desarrollo de rasgos frente a la cría convencional o a enfoques de OGM.
Cibus (NASDAQ:CBUS)는 제2세대 제초저항성(HT2) 편집 카놀라 형질의 FIELD 테스트 성공 결과를 발표했습니다. 2025년 재배 기간 동안 미국의 여러 위치에서 실시된 시험은 온실 시험의 긍정적 결과에 이어 실제 조건에서도 형질의 성능을 검증했습니다.
HT2 형질은 잡초 관리 능력을 향상시켜 제초제 적용 횟수를 줄이고 다른 제초저항 형질과의 호환성을 제공합니다. 이 개발은 Cibus의 Rapid Trait Development System™ (RTDS®)가 전통적인 육종이나 GMO 접근 방식에 비해 형질 개발 시간을 크게 단축한다는 것을 보여줍니다.
Cibus (NASDAQ:CBUS) a annoncé des résultats positifs d'essais sur le terrain pour sa caractéristique de tolérance aux herbicides (HT2) de deuxième génération chez le canola édité. Les essais, menés dans plusieurs sites aux États-Unis au cours de la saison de croissance 2025, ont validé les performances de la caractéristique dans des conditions réelles après des résultats positifs en serre.
La caractéristique HT2 offre des capacités de gestion des mauvaises herbes améliorées, permettant moins d'applications d'herbicides et une compatibilité avec d'autres traits de résistance aux herbicides. Cette évolution démontre l'efficacité du Rapid Trait Development System™ (RTDS®) de Cibus, qui réduit considérablement le temps de développement des traits par rapport aux méthodes de sélection traditionnelles ou aux approches OGM.
Cibus (NASDAQ:CBUS) hat erfolgreiche Ergebnisse von Feldversuchen für das zweite Generation-Herbizid-Toleranz-Editier-Canola-Merkmal HT2 bekannt gegeben. Die Versuche, an mehreren Standorten in den USA während der Saison 2025 durchgeführt, validierten die Leistung des Merkmals unter realen Bedingungen nach positiven Gewächshausversuchen.
Das HT2-Merkmal bietet verbesserte Unkrautbekämpfungsfähigkeiten, ermöglicht weniger Herbizidanwendungen und ist mit anderen Herbizidresistenzmerkmalen kompatibel. Diese Entwicklung demonstriert die Wirksamkeit des Rapid Trait Development System™ (RTDS®) von Cibus, das die Merkmalsentwicklungszeit im Vergleich zu herkömmlicher Züchtung oder GMO-Ansätzen signifikant reduziert.
شركة Cibus (بورصة ناسداك: CBUS) أعلنت عن نتائج ناجحة في الاختبارات الميدانية لطراز HT2، وهو تفاعل تعديل القنّالة بتحمل مبيدات الأعشاب من الجيل الثاني. الاختبارات، التي أُجريت في مواقع متعددة بالولايات المتحدة خلال موسم النمو 2025، أكّدت أداء الطراز في ظل ظروف واقعية عقب نتائج إيجابية من البيوت الزجاجية.
يقدم الطراز HT2 قدرات محسّنة لإدارة الأعشاب الضارة، مما يسمح بتقليل تطبيقات المبيدات والتوافق مع صفات مقاومة مبيدات الأعشاب الأخرى. هذا التطور يبيّن فعالية Rapid Trait Development System™ (RTDS®) من Cibus، الذي يقلّص بشكل كبير وقت تطوير الصفة مقارنةً بالطرق التقليدية في التربية أو أساليب التعديل الوراثي.
Cibus (NASDAQ:CBUS) 宣布其第二代除草剂耐受性（HT2）经过基因编辑的油菜性状在田间试验中的成功结果。试验在2025年美国产地多点进行，验证在真实条件下该性状的表现，继温室试验的积极结果之后。
HT2性状提供了更强的杂草控制能力，能够减少除草剂施用次数，并与其他抗除草剂性状兼容。这表明Cibus的快速性状开发系统™（RTDS®）的有效性，与传统育种或转基因方法相比，它显著缩短了性状开发时间。
- Successful field trial validation of HT2 trait in real-world conditions
- Technology enables fewer herbicide applications for weed control
- HT2 trait can be stacked with other herbicide resistance traits for greater flexibility
- Demonstrates effectiveness of proprietary RTDS technology for rapid trait development
- Field trials limited to US locations only
- Commercial availability timeline not specified
Insights
Cibus' successful field trials of HT2 Canola validate their gene editing platform and advance commercialization timeline for an important crop management solution.
Cibus has reached a significant development milestone with their second-generation herbicide tolerance (HT2) trait in Canola successfully completing field trials. This progression from greenhouse testing to real-world field validation demonstrates the trait's commercial viability and advances their go-to-market strategy through potential seed licensing partnerships.
The HT2 trait addresses a critical agricultural challenge - herbicide-resistant weeds that threaten crop yields. By enabling tolerance to additional herbicides, this trait provides farmers with more flexible weed management options. The technology allows for either standalone use or 'stacking' with other herbicide resistance traits, giving growers a more comprehensive toolkit for combating increasingly resistant weed populations.
What's particularly notable is the demonstration of Cibus' Rapid Trait Development System™ (RTDS®) technology platform. This proprietary gene editing approach significantly accelerates trait development compared to conventional breeding or GMO methods. The successful field validation reinforces the platform's ability to deliver complex genetic edits with predictable outcomes and shorter development timelines.
For Cibus' business model, the positive results strengthen their position as they pursue licensing opportunities with seed companies. This represents a crucial step toward commercialization and potential revenue generation. The advancement also bolsters Cibus' broader trait portfolio strategy across multiple crops, potentially expanding their addressable market.
Field testing confirms efficacy of HT2 trait in Canola under real-world conditions
HT2 trait will be offered to potential seed licensing partners for introduction into commercial Canola seed products
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company developing and licensing advanced gene edited plant traits that enable improved productivity, higher yields, lower input costs, and more sustainable farming, today announced the completion of field testing for its second-generation herbicide tolerance (HT2) edited Canola with positive results.
“Our second-generation herbicide tolerance edited canola previously performed well in greenhouse trials and has now shown positive results in our 2025 Canola field trials,” said Jim Radtke, PhD, Senior VP of Product Development at Cibus. “Achieving this milestone is an important step toward providing the Canola industry with a more effective, flexible tool for weed management, and it reflects the continued progress we are making in rapidly delivering innovative, sustainable trait solutions.”
Field testing is an essential step in validating trait performance under real-world conditions. Following successful greenhouse evaluations, Cibus conducted HT2 Canola field trials during the 2025 growing season at multiple US locations. Because growers often rely on multiple herbicides to manage weed pressure in their fields, traits like HT2 can help improve control with fewer herbicide applications. In addition, HT2 can also be “stacked” with other herbicide resistance traits, giving growers additional options and greater flexibility in their approach to weed management.
“Our technologies, which allow for complex edits that enhance productivity, hold great promise for the future of agriculture and we are very pleased to see the validation of our work in this season’s field trials for HT2 in Canola,” said Greg Gocal, PhD, Co-Founder, Executive VP and Chief Scientific Officer at Cibus. “Cibus continues to exhibit its ability to develop novel traits using its timebound and predicable approach with an aim of delivering higher yields, better crop management, and more nutritious foods while drastically shortening the time of development, reducing cost and enhancing speed to market for the benefit of growers.”
Cibus’ weed management solutions aim to deliver crop seeds with tolerance in both existing and novel herbicides, giving farmers new and more effective options for managing weeds. Traits such as HT2 are designed to help farmers protect yield by combatting weeds resistant to widely used herbicides and to support crops that require multiple herbicide solutions. The positive trial results are also a strong demonstration of Cibus’ Rapid Trait Development System™ (RTDS®), which enables trait development in significantly less time than conventional breeding or GMO approaches, and advances the Company’s strategy to build a broad portfolio of herbicide tolerance traits across multiple crops.
About Cibus
Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding Cibus' operational and financial performance, Cibus' liquidity and capital resources, the implementation and execution of cost savings initiatives, Cibus' strategy, future operations, prospects, and plans, including the anticipated receipt of commercial revenues and additional funding, are forward-looking statements. Cibus' assessment of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement. Because this involves such risks and uncertainties, the Company could use its available capital resources sooner than it currently expects. Forward-looking statements may be identified by words such as "anticipate," "believe," "intend," "expect," "plan," "scheduled," "could," "would" and "will," or the negative of these and similar expressions.
These forward-looking statements are based on the current expectations and assumptions of Cibus' management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. Cibus' actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: Cibus' need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; changes in expected or existing competition; challenges to Cibus' intellectual property protection and unexpected costs associated with defending intellectual property rights; increased or unanticipated time and resources required for Cibus' platform or trait product development efforts; Cibus' reliance on third parties in connection with its development activities; challenges associated with Cibus' ability to effectively license its productivity traits and sustainable ingredient products; the risk that farmers do not recognize the value in germplasm containing Cibus' traits or that farmers and processors fail to work effectively with crops containing Cibus' traits; delays or disruptions in the Company's platform or trait product development efforts, particularly with respect to its non-Rice and non-disease projects in light of the Company's realigned strategic priorities; challenges that arise in respect of Cibus' production of high-quality plants and seeds cost effectively on a large scale; Cibus' dependence on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses; regulatory developments that disfavor or impose significant burdens on gene-editing processes or products; delays and uncertainties regarding regulatory developments in the European Union; Cibus' ability to achieve commercial success; commodity prices and other market risks facing the agricultural sector; technological developments that could render Cibus' technologies obsolete; changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates; dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on Cibus' ability to execute on its business plan; the Company's assessment of the period of time through which its financial resources will be adequate to support operations; and other important factors discussed in the "Risk Factors" section of Cibus' Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements.
In addition, the forward-looking statements included in this press release represent Cibus' views as of the date hereof. Cibus specifically disclaims any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus' views as of any date subsequent to the date hereof.
CIBUS CONTACTS:
INVESTOR RELATIONS
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
media@cibus.com
Colin Sanford
colin@bioscribe.com
FAQ
What were the results of Cibus (CBUS) HT2 Canola field trials in 2025?
How does Cibus's HT2 trait benefit Canola farmers?
What is Cibus's Rapid Trait Development System (RTDS)?
Where were the Cibus HT2 Canola field trials conducted?
What is the commercial status of Cibus's HT2 Canola trait?
